

November 28, 2024

BSE Limited (Scrip Code: 500124)

Dear Sir/Madam,

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Further to our intimation dated November 27, 2024, and your e-mail dated November 28, 2024, we hereby inform that our wholly owned subsidiary companies in Germany – betapharm Arzneimittel GmbH and Reddy Holding GmbH have received the fine notices from Federal Administration Office, Bad Homburg, Germany. The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are provided hereunder:

A) Name of the authority	Federal Administration Office, Homburg, Germany
B) Nature and details of the action(s) taken, initiated or order(s) passed	The Company received the fine notices from Federal Administration Office, Bad Homburg, Germany for breach of legal obligation to register the “beneficial owners” in the German Transparency Register for following two wholly owned subsidiary companies incorporated in Germany. The details of fine imposed is as follows:  <ul style="list-style-type: none"> <li>• betapharm Arzneimittel GmbH - € 8,584.63</li> <li>• Reddy Holding GmbH - €10,569.13</li> </ul>
C) Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	Date of receipt of orders: October 22, 2024.  The delay in disclosure is due to the delay in receipt of information and copy of fine notices issued by Federal Administration Office, Bad Homburg, Germany from above said subsidiaries.
D) Details of the violation(s)/ contravention(s) committed or alleged to be committed	Breach of legal obligation to register the “beneficial owners” in the German Transparency Register within the prescribed timeline.  Further, the Company has taken the corrective action and registered the beneficial ownership of the said subsidiaries in German Transparency Register.
E) Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	As stated in point (B) above. Based on our evaluation, there is no material impact on the financials, operations, or other activities of the Company.

Kindly take the same on record and oblige.

Thanking you,

Yours faithfully,

For **Dr. Reddy's Laboratories Limited**

**K Randhir Singh**

*Company Secretary, Compliance Officer & Head-CSR*